In Conversation

COFEPRIS decided to introduce ten regulations for health purposes, and three of these were specifically for medical devices. This prioritization underscores the importance of our contributions…

Our portfolio is deliberately diversified to mitigate reliance on any single segment  

Latin America offers companies the opportunity to perform well and generates excellent performance examples to showcase around the world

The issue of health is simply not a priority for the government. This is evident through the way they minimise many important aspects of the process…

In Mexico 85 percent of the medicines consumed by the population are produced in the country itself. For this reason, Mexico is considered one of the…

We are on a permanent learning curve with the government and pushing forward as much as we can for new molecule approvals, so patients have access…

LatAm as a region offers many opportunities for innovation. The key point and the biggest responsibility for us in this region is to continue working to…

The Mexican industry is going through a period of uncertainty, but I believe we will be in a better position in three or four years. Companies…

Our priority is improving patient access to our products. The [Mexican] government’s expansion of coverage to those segments of the population that do not have the…

In my experience, companies dedicated to particular therapeutic areas seem to be able to learn faster compared to companies with broader portfolios

The upcoming three years are crucial and UCB Mexico wants to play a role elevating the standard of care in our country

More certainty, a longer-term vision of what is going to happen, and a consideration of how all stakeholders can benefit are needed [in Mexican healthcare]

We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here